SCHEMBL22276997

SCHEMBL22276997

O=CCn1cc(-c2ccc(C(=O)O)cc2)nn1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 3/20 0.51
▸ MEN1 O00255 3/20 0.49
▸ KMT2A Q03164 3/20 0.49
▸ CASP3 P42574 1/20 0.49
▸ SENP8 Q96LD8 1/20 0.49
▸ SENP7 Q9BQF6 1/20 0.49
▸ SENP6 Q9GZR1 1/20 0.49
▸ ALOX5 P09917 2/20 0.47
▸ PTGES2 Q9H7Z7 1/20 0.47
▸ NPC1 O15118 2/20 0.45
▸ RAB9A P51151 2/20 0.45
▸ NR1H4 Q96RI1 1/20 0.45
▸ UCHL5 Q9Y5K5 2/20 0.45
▸ UCHL1 P09936 1/20 0.45
▸ UCHL3 P15374 1/20 0.45
▸ EP300 Q09472 3/20 0.44
▸ PTGES O14684 1/20 0.42
▸ CYP19A1 P11511 1/20 0.42
▸ P2RY14 Q15391 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22276761 0.82 SRC (0.58) SRCMEN1KMT2ACASP3SENP8
SCHEMBL3768428 0.79 SRC (0.51) SRCMEN1KMT2ACASP3SENP8
SCHEMBL22530280 0.78 SRC (0.53) SRCMEN1KMT2ACASP3SENP8
SCHEMBL27144814 0.78 SRC (0.50) SRCMEN1KMT2ACASP3SENP8
SCHEMBL22276921 0.76 SRC (0.58) SRCMEN1KMT2ACASP3SENP8
SCHEMBL22530963 0.76 SRC (0.48) SRCMEN1KMT2ACASP3SENP8
SCHEMBL22531104 0.76 SRC (0.51) SRCMEN1KMT2ACASP3SENP8
SCHEMBL30148152 0.76 MEN1 (0.66) MEN1KMT2ACASP3SENP8SENP7
SCHEMBL22530335 0.75 SRC (0.47) SRCMEN1KMT2ACASP3SENP8
SCHEMBL27146580 0.75 NPC1 (0.51) SRCMEN1KMT2ACASP3SENP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11773129-B2 Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) 2023-10-03 — — US disclosed
US-20200239512-A1 METHODS OF PREVENTING OR TREATING ATHEROSCLEROSIS WITH INHIBITORS OF SPECIFIC ISOENZYMES OF HUMAN NEURAMINIDASE VALORISATION HSJ, LIMITED PARTNERSHIP (CA) 2020-07-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200239512-A1 METHODS OF PREVENTING OR TREATING ATHEROSCLEROSIS WITH INHIBITORS OF SPECIFIC ISOENZYMES OF HUMAN NEURAMINIDASE NEU1, NEU3, NEU2 SRC 4128/4885MEN1 1088/4885KMT2A 3830/4885
US-11773129-B2 Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase NEU1, NEU3, NEU2 SRC 4128/4885MEN1 1088/4885KMT2A 3830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback